107 related articles for article (PubMed ID: 23791886)
1. Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatment in vivo.
Kulkarni-Datar K; Orsulic S; Foster R; Rueda BR
Cancer Lett; 2013 Oct; 339(2):237-46. PubMed ID: 23791886
[TBL] [Abstract][Full Text] [Related]
2. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.
Ma L; Lai D; Liu T; Cheng W; Guo L
Acta Biochim Biophys Sin (Shanghai); 2010 Sep; 42(9):593-602. PubMed ID: 20705681
[TBL] [Abstract][Full Text] [Related]
3. CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide.
Banerjee S; Nomura A; Sangwan V; Chugh R; Dudeja V; Vickers SM; Saluja A
Clin Cancer Res; 2014 May; 20(9):2388-99. PubMed ID: 24634377
[TBL] [Abstract][Full Text] [Related]
4. ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature.
Roy L; Samyesudhas SJ; Carrasco M; Li J; Joseph S; Dahl R; Cowden Dahl KD
Oncotarget; 2014 Sep; 5(18):8355-66. PubMed ID: 25327563
[TBL] [Abstract][Full Text] [Related]
5. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.
Curley MD; Therrien VA; Cummings CL; Sergent PA; Koulouris CR; Friel AM; Roberts DJ; Seiden MV; Scadden DT; Rueda BR; Foster R
Stem Cells; 2009 Dec; 27(12):2875-83. PubMed ID: 19816957
[TBL] [Abstract][Full Text] [Related]
6. Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma.
Yang JP; Liu Y; Zhong W; Yu D; Wen LJ; Jin CS
Chin Med J (Engl); 2011 Apr; 124(7):1055-60. PubMed ID: 21542968
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
8. In Ovarian Cancer Multicellular Spheroids, Platelet Releasate Promotes Growth, Expansion of ALDH+ and CD133+ Cancer Stem Cells, and Protection against the Cytotoxic Effects of Cisplatin, Carboplatin and Paclitaxel.
Casagrande N; Borghese C; Agostini F; Durante C; Mazzucato M; Colombatti A; Aldinucci D
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809553
[TBL] [Abstract][Full Text] [Related]
9. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.
Kryczek I; Liu S; Roh M; Vatan L; Szeliga W; Wei S; Banerjee M; Mao Y; Kotarski J; Wicha MS; Liu R; Zou W
Int J Cancer; 2012 Jan; 130(1):29-39. PubMed ID: 21480217
[TBL] [Abstract][Full Text] [Related]
10. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.
Casagrande N; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Clin Cancer Res; 2014 Nov; 20(21):5496-506. PubMed ID: 25231401
[TBL] [Abstract][Full Text] [Related]
11. A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells in S/G2/M phases.
Yano S; Tazawa H; Hashimoto Y; Shirakawa Y; Kuroda S; Nishizaki M; Kishimoto H; Uno F; Nagasaka T; Urata Y; Kagawa S; Hoffman RM; Fujiwara T
Clin Cancer Res; 2013 Dec; 19(23):6495-505. PubMed ID: 24081978
[TBL] [Abstract][Full Text] [Related]
12. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
[TBL] [Abstract][Full Text] [Related]
13. Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells.
Yang Q; Zhang T; Wang C; Jiao J; Li J; Deng Y
Eur J Pharm Biopharm; 2014 Nov; 88(3):737-45. PubMed ID: 25460146
[TBL] [Abstract][Full Text] [Related]
14. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin and sodium butyrate, separate--yes, but combined--never.
Gurtowska N; Kloskowski T; Olkowska J; Bajek A; Debski R; Zielaskowska J; Drewa T
Acta Pol Pharm; 2013; 70(1):153-61. PubMed ID: 23610971
[TBL] [Abstract][Full Text] [Related]
16. In vivo 5FU-exposed human medullary thyroid carcinoma cells contain a chemoresistant CD133+ tumor-initiating cell subset.
Kucerova L; Feketeova L; Kozovska Z; Poturnajova M; Matuskova M; Nencka R; Babal P
Thyroid; 2014 Mar; 24(3):520-32. PubMed ID: 24073856
[TBL] [Abstract][Full Text] [Related]
17. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.
Tang KH; Ma S; Lee TK; Chan YP; Kwan PS; Tong CM; Ng IO; Man K; To KF; Lai PB; Lo CM; Guan XY; Chan KW
Hepatology; 2012 Mar; 55(3):807-20. PubMed ID: 21994122
[TBL] [Abstract][Full Text] [Related]
18. Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3.
Guo R; Wu Q; Liu F; Wang Y
Oncol Rep; 2011 Jan; 25(1):141-6. PubMed ID: 21109969
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of BMI-1 in cancer stem cells of laryngeal carcinoma.
Yu D; Liu Y; Yang J; Jin C; Zhao X; Cheng J; Liu X; Qi X
Cell Biochem Biophys; 2015 Jan; 71(1):261-9. PubMed ID: 25241082
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
Skubitz AP; Taras EP; Boylan KL; Waldron NN; Oh S; Panoskaltsis-Mortari A; Vallera DA
Gynecol Oncol; 2013 Sep; 130(3):579-87. PubMed ID: 23721800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
